{"title":"How We Pay Matters: The Ethics of Payment Mechanisms for Research Participants","authors":"Annie Harper, Anthony Pavlo, Steven Olsen","doi":"10.1002/eahr.70026","DOIUrl":"https://doi.org/10.1002/eahr.70026","url":null,"abstract":"<div>\u0000 \u0000 <p>This article raises concerns about the ethical implications of how research participants are paid to participate in studies, with a particular focus on marginalized populations. Traditionally, research participants were paid via cash, gift cards, or checks, but in the last decade many research institutions have started using prepaid reloadable debit cards. This shift has been problematic for many research participants who often face delayed access to funds, withdrawal fees, limited ability to make essential purchases for which they need cash, and the risk of card freezes. A problem for people receiving disability benefits is that they must provide a social security number to be paid on a prepaid card, and payments are reported to the Internal Revenue Service, potentially jeopardizing benefits and triggering unexpected tax liabilities. During the Covid-19 pandemic, some researchers used fintech (digital payment via apps such as Venmo, Cash App, PayPal) to pay participants remotely; many preferred the immediacy, accessibility, and relative lack of surveillance of this form of payment compared to prepaid cards. Despite this, many universities have reverted to prepandemic policies favoring prepaid cards and prohibiting fintech due to administrative controls and compliance concerns. We argue that this inflexibility imposes financial stress on already vulnerable participants, underscoring a moral imperative for research institutions to reconsider payment methods and better align policies with participant needs and the realities of modern financial inclusion.</p>\u0000 </div>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 6","pages":"40-43"},"PeriodicalIF":0.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Logan Neitzke-Spruill, Jill Oliver Robinson, Alison Purcell, Dominic Sisti, Amy L. McGuire, Holly Fernandez Lynch
{"title":"Researchers’ Experiences with IRB Oversight of Psychedelic Research","authors":"Logan Neitzke-Spruill, Jill Oliver Robinson, Alison Purcell, Dominic Sisti, Amy L. McGuire, Holly Fernandez Lynch","doi":"10.1002/eahr.70033","DOIUrl":"https://doi.org/10.1002/eahr.70033","url":null,"abstract":"<p>Previous research raises concern that conservative institutional review board (IRB) approaches regarding stigmatized issues and vulnerable groups could similarly arise as an impediment to research with psychedelic drugs. We interviewed 20 US researchers who had been a principal investigator on at least one research protocol involving psychedelics about their experiences with IRB oversight and perspectives regarding what IRBs need to know. Respondents reported that their IRBs raised concern and asked questions about participant safety, consent, legal issues, and data security and confidentiality, typical domains for IRB consideration. They also mentioned several IRB knowledge gaps or misunderstandings about psychedelics, primarily about risks and safety, while emphasizing the importance of IRBs’ understanding of psychedelic drug effects. Despite IRB concerns and misunderstandings, all study respondents ultimately reported positive or neutral current experiences with IRBs reviewing their protocols for research with psychedelics, which they often attributed to cultivating strong IRB relationships and helping IRBs achieve adequate knowledge about these types of studies. Although investigators in our study did not perceive their IRBs to be a significant barrier to research with psychedelics, less experienced investigators and IRBs may face different outcomes. As research with psychedelics continues to increase, both researchers and IRBs should be responsive to continued scientific developments and emergent best practices.</p>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 6","pages":"6-19"},"PeriodicalIF":0.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eahr.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Julia E. H. Brown, Leslie S. Riddle, Emma Canepa, Billie Lianoglou, Dawn Gano, Teresa N. Sparks, Jodi Halpern
{"title":"The Primary Reasons People Participate in Maternal-Fetal Phase I Clinical Trials Are Psychosocial","authors":"Julia E. H. Brown, Leslie S. Riddle, Emma Canepa, Billie Lianoglou, Dawn Gano, Teresa N. Sparks, Jodi Halpern","doi":"10.1002/eahr.70025","DOIUrl":"https://doi.org/10.1002/eahr.70025","url":null,"abstract":"<p>Recent critiques of ethical guidance for maternal-fetal therapy clinical trials has highlighted the need to weigh maternal, fetal, and societal interests, respectively, while deprioritizing psychosocial reasons for participation. Psychosocial reasons refer to the psychological and social influences on study participants’ decisions, and they are often central to considerations about informed consent. However, psychosocial reasons are described as too indirect, subjective, and vague to incorporate into prenatal clinical and regulatory frameworks. This qualitative study examined the perspectives of 11 individuals (within eight couples) enrolled in one of two maternal-fetal therapy phase I clinical trials for rare genetic conditions. Interviews revealed that motivations to participate were primarily psychosocial, including existential concerns given prior bereavement and/or fear of loss; temporal control through taking action as opposed to feeling passive; hope and optimism; and intergenerational and social motivations given one's family experience with disease and desire for social connections. Psychosocial reasons for participating ought to be given more consideration in ethical frameworks for maternal-fetal therapy phase I clinical trials, as well as in the approach to informed consent. It is important for clinical research teams to be especially conscientious to ensure appreciation for participants’ reasons for participating that extend beyond typical frameworks of clinical risk/benefit, and to support participants who might harbor optimistic expectations of medical procedures as they transition to postnatal realities.</p>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 6","pages":"20-31"},"PeriodicalIF":0.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eahr.70025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Who Is Being Studied? How Retrospective Chart Reviews Can Obscure about Whom Researchers Obtain Information","authors":"Kenneth A. Richman","doi":"10.1002/eahr.70021","DOIUrl":"https://doi.org/10.1002/eahr.70021","url":null,"abstract":"<div>\u0000 \u0000 <p>When researchers submit to an institutional review board (IRB) protocols to conduct retrospective chart reviews, they identify the patients whose charts are to be reviewed as the only human participants in their research study. However, a significant number of these studies are conducted at least in part to draw conclusions about the behavior of health care providers. As such, these health care providers are living individuals about whom the researchers will obtain identifiable private information for research. Yet in reviewing protocols submitted to an IRB, this author has encountered many retrospective chart reviews that fail to list health care providers as the subjects of a research study, even when the primary research question is about provider behaviors such as prescribing or ordering tests. This paper describes the practice of obscuring who is being studied in research involving retrospective chart reviews, shares examples of such studies, and explores how the practice of obscuring who researchers are obtaining information about violates principles that should guide human subjects protections. The paper argues that the status of a study as quality improvement/assessment does not excuse these violations.</p>\u0000 </div>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 6","pages":"32-39"},"PeriodicalIF":0.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Subtle Crisis: Public Domain Genomes and the Ethics of Translational Infrastructure","authors":"Jonathan Edward LoTempio Jr.","doi":"10.1002/eahr.70032","DOIUrl":"https://doi.org/10.1002/eahr.70032","url":null,"abstract":"<p>Public domain human genomic resources are infrastructure: tools researchers use to ask basic biological questions whose answers are then translated into products and care. Translational science now asks them to support an expanding set of tasks, including clinical variant interpretation for diverse populations, pharmacogenomic prescribing, polygenic risk prediction, and the training of clinical artificial intelligence. The corpus of public domain genomes, due in large part to upstream recruitment choices, is not fit for these purposes, and the gap between discovery and translation is widening. This essay argues that closing the gap requires treating public domain genomic infrastructure as a particular object of translational bioethics rather than a technical precondition for it. The limited number of genomes in the public domain relative to the broader genomic record, and the typology-friendliness of how that record represents human variation, are two faces of the same set of upstream choices. Reversing them is not a matter of more sampling under existing terms; it is a matter of building infrastructure of a particular kind; infrastructure made from people. That category, common in genomics but absent from the rest of science, demands an ethical apparatus the field has not yet built. Here we consider the commitments such an apparatus requires, and argue that where, how, and with whom we build genomic infrastructure is itself an ethics question the field has largely declined to ask.</p>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 5","pages":"46-53"},"PeriodicalIF":0.0,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eahr.70032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148878476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stephanie R. Morain, Caleigh Propes, Ruth R. Faden
{"title":"IRB Policies on the Inclusion of Pregnant Women in Research","authors":"Stephanie R. Morain, Caleigh Propes, Ruth R. Faden","doi":"10.1002/eahr.70020","DOIUrl":"https://doi.org/10.1002/eahr.70020","url":null,"abstract":"<div>\u0000 \u0000 <p>Pregnant women have historically been excluded from clinical research, denying pregnant women the benefits of the societal investment in biomedical research and potential direct benefits from research participation. National and international guidance documents have called upon institutional review boards (IRBs) to institute policies to establish the expectation for inclusion of pregnant women in clinical research and require justification when pregnant women are excluded. However, only limited evidence exists regarding the extent to which IRBs have adopted policies consistent with these recommendations. We reviewed IRB policies and related guidance documents from the top 50 research institutions in the United States and the two largest independent IRBs. Four academic and one independent IRB included language that reinforced the view that pregnant women should not be included in research. Conversely, eight academic institutions included language that expressly fostered a culture of inclusion, and five academic institutions included language describing a requirement to justify decisions to exclude pregnant women. Neither independent IRB required justification for exclusion. While some institutions have implemented changes to advance the goal of ethical inclusion, considerable gaps remain between widely endorsed recommendations that IRBs contribute to facilitating appropriate inclusion of pregnant women in research and on-the-ground IRB policies.</p>\u0000 </div>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 5","pages":"6-13"},"PeriodicalIF":0.0,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148878356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bhuchitra Singh, Aileen Zhang, Arun H. Patil, Abigail Coco, Ibelle Madera, Sarah Olson, Kristin Voegtline, Enrique Schisterman, James Segars
{"title":"Perspectives of Researchers and Research Team Members Regarding Their Experience with sIRBs","authors":"Bhuchitra Singh, Aileen Zhang, Arun H. Patil, Abigail Coco, Ibelle Madera, Sarah Olson, Kristin Voegtline, Enrique Schisterman, James Segars","doi":"10.1002/eahr.70018","DOIUrl":"https://doi.org/10.1002/eahr.70018","url":null,"abstract":"<div>\u0000 \u0000 <p>Our study examines the perspectives of researchers and other research team members who conducted National Institutes of Health (NIH)-funded studies about their use of a single institutional review board (sIRB) review and onboarding process. More than 84% (n = 639) of respondents agreed that NIH-sponsored multisite clinical trials benefit from sIRB use. A higher proportion of super-users (>10 studies) of an sIRB than moderate users (1-10 studies) described the onboarding process positively (n = 119, 56% vs. n = 225, 42%, p = .01) and found sIRBs to be more cost-effective than a site-specific model (n = 113, 53.05% vs. n = 221, 41%, p <.01). Timeline delays were experienced by over 90% (n = 680) of respondents and an increased administrative burden was reported by almost half (n = 353, 47%) of respondents. Respondents described increased administrative burden for sIRB approvals when an institution-specific application was required (n = 299, 51% vs. n = 30, 29%, p <.01). Most researchers judged sIRBs to be beneficial. However, delays in approval, increased administrative burden, and associated compulsory institution-specific applications posed logistical challenges for researchers. Reform efforts must focus on aligning sIRB and local study site standards to optimize sIRB study review.</p>\u0000 </div>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 5","pages":"26-36"},"PeriodicalIF":0.0,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148878358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"When a Human-in-the-Loop Amplifies the Risk of Misalignment: Considerations for Research Ethics Oversight","authors":"Erin Taylor","doi":"10.1002/eahr.70024","DOIUrl":"https://doi.org/10.1002/eahr.70024","url":null,"abstract":"<div>\u0000 \u0000 <p>Human-in-the-loop (HITL) approaches are commonly proposed to address alignment challenges arising from the use of large language models in research ethics oversight. This paper argues that, paradoxically, a HITL can amplify the risk of misalignment. Using the example of protocol triage in research ethics oversight, I demonstrate how reliance on imperfect proxies (observable stand-ins for ethical principles) creates a fundamental proxy-target gap in ethics use-cases. While human ethics committee reviewers are intended to supply phenomenological and causal judgments necessary to bridge this gap, their involvement inadvertently introduces new vulnerabilities: hallucination, over-reliance, reward hacking, and sycophancy. Each vulnerability arises directly from the interaction between human feedback signals and model optimization strategies. I outline key mitigation techniques, including retrieval grounding, calibration drills, structured prompting, and adversarial debate, explaining their distinct costs and benefits. Effective HITL oversight therefore demands specialized ethics committee reviewer competencies. These reviewers must recognize model vulnerabilities, understand mitigation trade-offs, and strategically deploy mitigations to preserve justificational alignment without sacrificing efficiency gains.</p>\u0000 </div>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 5","pages":"14-25"},"PeriodicalIF":0.0,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148878357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Whanyichukwu Frank-Ito, Lori Ann Eldridge, Jennifer Matthews
{"title":"Digital Deception: Survey Bots and the Ethics of Data Integrity","authors":"Whanyichukwu Frank-Ito, Lori Ann Eldridge, Jennifer Matthews","doi":"10.1002/eahr.70017","DOIUrl":"https://doi.org/10.1002/eahr.70017","url":null,"abstract":"<p>The rapid growth of artificial intelligence and automated systems has significantly impacted digital survey-based research, particularly when recruitment is conducted via social media platforms. This case study details the erosion of data integrity in a 2025 follow-up survey, originally designed to replicate a successful 2021 study. Despite implementing increasingly sophisticated antifraud mechanisms such as CAPTCHA, IP geo-restrictions, and behavioral validation, survey bots repeatedly infiltrated the study, rendering the dataset unusable. This highlights a critical tension between broad digital accessibility and the vulnerability of online research to fraud. Moreover, the use of financial incentives to participate in research, while effective in increasing response rates, was found to amplify bot activity and raise ethical dilemmas surrounding compensation and data quality. As automated deception continues to evolve, researchers must navigate a complex landscape where conventional protections are no longer sufficient. The authors call for the urgent development of fieldwide standards, institutional support, and robust fraud prevention strategies to preserve the methodological and ethical integrity of digital research. Without such measures, the viability of online recruitment and the trustworthiness of the resulting data remain at serious risk.</p>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 5","pages":"37-45"},"PeriodicalIF":0.0,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eahr.70017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148878359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Organ Chips and Translational Research: Identifying and Examining New Ethical Issues","authors":"Melanie Jeske","doi":"10.1002/eahr.70031","DOIUrl":"https://doi.org/10.1002/eahr.70031","url":null,"abstract":"<p>Organ chips, also known as organ-on-a-chip devices, tissue chips, or microphysiological systems, have emerged over the last decade as a promising translational technology amidst growing concern about the translational crisis between laboratory research and patient bedside. Pointing to high rates of failure between nonhuman animal models and safety and efficacy in humans, organ chips and similar new approach methods have attracted substantial public and private investment. As human-cell-based alternatives to animal models, organ chips promise more predictive, efficient, and ethical platforms for pharmaceutical and toxicity testing. Engineered cultivation systems that enable cells to assemble into tissue-like structures (e.g. kidney, brain, liver), organ chips mimic tissue architecture and function and live for extended periods of time. This essay considers the translational bioethics issues raised by organ chips, including those that arise early in development such as the obfuscation of cell-origin data, representation in design, and the normalization of conflicts of interest within commercialization-oriented translational science efforts. Integrating a translational bioethics lens from the outset, rather than deferring social and ethical implications analysis to downstream points in technology development and adoption, is essential to realizing the translational promise of organ chips while avoiding the reproduction of existing inequities and ethical conundrums.</p>","PeriodicalId":36829,"journal":{"name":"Ethics & human research","volume":"48 4","pages":"39-45"},"PeriodicalIF":0.0,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eahr.70031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148373126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}